Celgene Corp. has turned to China to expand its immuno-oncology pipeline, buying a stake in BeiGene (Beijing) Co. Ltd. and getting access to its investigational PD-1 inhibitor.
Celgene Eyes IO Growth With BeiGene China Pact
Celgene splashes $150m to buy a stake in BeiGene of China and $263m upfront to get rights to a PD-1 antibody that could catapult the US firmly up the immuno-oncology ladder.
